Skip to Content
Merck
CN
  • [Metabolic tolerance of isradipine. Evaluation after three months of therapy].

[Metabolic tolerance of isradipine. Evaluation after three months of therapy].

La Clinica terapeutica (1995-11-01)
D Panuccio, M R Trabatti, A Bernardini, A Capone
ABSTRACT

The aim of the present study was to evaluate efficacy on blood pressure values and metabolic tolerability of Isradipine, which was given to 15 mild hypertensive non diabetic subjects (average age 63.8 +/- 10.9 years), at the dosage of 5 mg once a day. Plasma lipids concentrations and oral glucose tolerance test (OGGT) with plasma insulin assay were carrid out before, after one and three months of therapy. The statistical analysis was done using the Student's t test for paired data. Isradipine showed a good efficacy on lowering high blood pressure. In no patients the drug induced impaired glucose tolerance. Isradipine had contrasting, but not statistically significant effects on lipid concentrations, namely, decrease of triglycerides, increased of any form of cholesterol (total, HDL, LDL), apoproteins and lipoprotein(a).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Isradipine, ≥98% (HPLC), solid
Isradipine, European Pharmacopoeia (EP) Reference Standard